Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon
AssigneeThe Regents of the University of Colorado
InventorsRoss Kedl, Phillip J. Sanchez, Catherine Haluszczak
Life of this patent
Estimating the term…
Abstract
A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
Claims13
A nucleic acid construct which encodes polypeptides which in combination elicit a synergistic effect on CD70 expression by dendritic cells and/or CD8+ T proliferation, activation or CD8+ T cell immune responses comprising:
- (i) a nucleic acid encoding an agonistic anti-CD40 antibody or agonistic binding fragment thereof, wherein said agonistic anti-CD40 antibody is a monoclonal antibody selected from CD40.4 (5c3) and S2C6;
- and
- (ii) a nucleic acid sequence encoding a type 1 interferon;
- and
- (iii) optionally a nucleic acid sequence encoding a desired antigen;
- wherein the sequences (i), (ii) and (iii) if present are operably linked to the same or different transcription regulatory sequences.
Dependencies are inferred from the claim text.